1. Alphyn Biologics reported positive pediatric results from its Phase 2a atopic dermatitis trial.
2. The trial met all primary and secondary endpoints in children aged 2 and older.
3. AB-101a is a novel topical candidate for mild-to-moderate atopic dermatitis (AD).
4. The trial evaluated the safety and efficacy of AB-101a, which treats immune and bacterial components of AD.
5. The safety profile of AB-101a supports long-term continuous use.
6. The randomized double-blind Phase 2a trial compared AB-101a with a vehicle control.
7. Primary efficacy endpoints included reduction of disease severity and minimal safety and side effects.
8. Secondary endpoints included improvement in Eczema Area and Severity Index (EASI) scores and itch reduction.
9. Alphyn plans to initiate a multinational Phase 2b trial with sites in the US, Europe, Canada, and Australia.
10. Alphyn Biologics is a clinical-stage dermatology company focused on developing first-in-class multi-target therapeutics for severe and prevalent skin diseases.